Seegene

096530 · KOSDAQ · Health Care · SMALL CAP

Provisional Q1 2026 results.

Seegene filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$88.8M (+11.3% year on year), operating profit of US$16.2M (+58.6% year on year) and net income of US$23.9M (+20.1% year on year).

Earnings(Operating results (consolidated) (preliminary) (fair disclosure))· FILED 2026-05-08· RCEPT 20260508900623

US$88.8MRevenue
+11.3%Revenue vs a year earlier
US$16.2MOperating profit

Converted at 1 USD ≈ ₩1,454.79 (filing-date rate, 2026-05-07 close)

What happened

Seegene filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$88.8M (+11.3% year on year), operating profit of US$16.2M (+58.6% year on year) and net income of US$23.9M (+20.1% year on year).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$88.8M
Revenue vs a year earlier+11.3%
Operating profitUS$16.2M
Net incomeUS$23.9M
PeriodQ1 2026 (consolidated)
Filed2026-05-08, Operating results (consolidated) (preliminary) (fair disclosure)
SourceDART rcept 20260508900623 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-05-08 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.